dm+d

Unassigned

New Medicines

Relapsed or refractory multiple myeloma (MM) - fourth-line or greater

Information

New molecular entity
Bristol Myers Squib
Bristol Myers Squibb

Development and Regulatory status

Discontinued
Discontinued
Discontinued

Category

B-cell maturation antigen (BCMA) targeting chimeric antigen receptor T cell (CAR-T) therapy. The product comprises autologous CD4+ and CD8+ T-cells transduced with a genetically-engineered lentiviral vector to express a BCMA-specific CAR.
The incidence in Europe is 4.5-6.0 per 100,000/year with a mortality rate of 4.1 per 100,000/year [1].
Relapsed or refractory multiple myeloma (MM) - fourth-line or greater
Intravenous